Revenue Growth
The Oncology Institute, Inc. reported a fiscal year 2024 revenue increase of 21.3% compared to 2023, driven by contributions from the California-based pharmacy and new capitation contracts.
Expansion into New Markets
The company successfully entered new markets outside of California, with significant contracts in Florida totaling over 200,000 lives, further expanding to 80,000 additional lives in early 2025.
Improved Financial Position
The Oncology Institute, Inc. reduced outstanding debt from $110 million to $86 million by early 2025 and raised $16.5 million in a private placement, improving financial flexibility.
Cash Flow Improvements
The company generated over $4 million of cash in Q4 2024, marking the second consecutive quarter of positive cash from operations.
Cost Efficiency
SG&A expenses decreased by 12% in Q4 2024 compared to Q4 2023, demonstrating operational efficiency and strategic execution.